Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne
Portfolio Pulse from
Dermata Therapeutics announced the completion of patient visits in its Phase 3 STAR-1 trial for XYNGARI™, a treatment for moderate-to-severe acne. Results are expected by March 2025.
March 04, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dermata Therapeutics has completed patient visits in its Phase 3 trial for XYNGARI™, a potential acne treatment. Results are anticipated by March 2025, which could impact the stock price.
The completion of patient visits in the Phase 3 trial is a significant milestone for Dermata. Positive results could lead to FDA approval, boosting the stock. The anticipation of results by March 2025 creates potential for stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100